Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Mechanistic Insights into the Role of MCP-1 in Diverse Liver Pathological Conditions: A Recent Update

In Press, (this is not the final "Version of Record"). Available online 06 January, 2025
Author(s): Sahil Dhengle, Krushna Ch Maharana, Sarasa Meenakshi and Sanjiv Singh*
Published on: 06 January, 2025

DOI: 10.2174/0113816128332969241120030733

Price: $95

TIMBC 2025
Abstract

Monocyte chemoattractant protein-1 (MCP-1) is regarded as a crucial proinflammatory cytokine that controls the migration and entry of macrophages. It has been demonstrated that chemokine ligand 2 and its receptor, Chemokine receptor 2, are both implicated in several liver disorders. In a similar context, immunity mediators are overexpressed and stimulated by MCP-1. Additionally, MCP-1 alters the physiology of the hepatocytes, promoting immunologic and inflammatory responses beyond regular metabolism. Alcoholism and other factor including abnormal diet stimulate the liver’s synthesis of MCP-1, which can result in inflammation in liver. Studies shows how MCP-1' linked to various liver disorders like Alcoholic liver disease, liver fibrosis, Non- alcoholic fatty liver disease, Hepatitis, Hepatic steatosis, hepatocellular cancer, primary biliary cirrhosis. MCP-1 not only predicts the onset, progression, and prognosis of the illness, but it is also directly related to the degree and stage of liver inflammation. In this review, we will explore the mechanism and connection between MCP-1’s overexpression in liver disorders, further how it can be linked as a therapeutic biomarker in the above scenario.

Keywords: Chemokines, monocyte chemotactic protein-1, inflammation, liver disorders, oxidative stress.


Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy
  翻译: